Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Go back to Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death| Pfizer Inc. (NYSE: PFE) | Delayed: 27.66 +0.02 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.76 | |||
| Day Low | $27.34 | EPS | $1.65 | |||
| Volume | 75,587,710 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 27.66 +0.02 (0.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $27.64 | 52 Week High | $37.39 | |||
| Open | $27.64 | 52 Week Low | $28.25 | |||
| Day High | $27.66 | P/E | 16.76 | |||
| Day Low | $27.34 | EPS | $1.65 | |||
| Volume | 75,587,710 | |||||
